These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 30962505)

  • 1. SATB2 and CDX2 are prognostic biomarkers in DNA mismatch repair protein deficient colon cancer.
    Ma C; Olevian D; Miller C; Herbst C; Jayachandran P; Kozak MM; Chang DT; Pai RK
    Mod Pathol; 2019 Jul; 32(8):1217-1231. PubMed ID: 30962505
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Loss of SATB2 Expression in Colorectal Carcinoma Is Associated With DNA Mismatch Repair Protein Deficiency and BRAF Mutation.
    Ma C; Olevian DC; Lowenthal BM; Jayachandran P; Kozak MM; Chang DT; Pai RK
    Am J Surg Pathol; 2018 Oct; 42(10):1409-1417. PubMed ID: 30001238
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BRAF-mutated, microsatellite-stable adenocarcinoma of the proximal colon: an aggressive adenocarcinoma with poor survival, mucinous differentiation, and adverse morphologic features.
    Pai RK; Jayachandran P; Koong AC; Chang DT; Kwok S; Ma L; Arber DA; Balise RR; Tubbs RR; Shadrach B; Pai RK
    Am J Surg Pathol; 2012 May; 36(5):744-52. PubMed ID: 22314188
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular markers identify subtypes of stage III colon cancer associated with patient outcomes.
    Sinicrope FA; Shi Q; Smyrk TC; Thibodeau SN; Dienstmann R; Guinney J; Bot BM; Tejpar S; Delorenzi M; Goldberg RM; Mahoney M; Sargent DJ; Alberts SR
    Gastroenterology; 2015 Jan; 148(1):88-99. PubMed ID: 25305506
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Loss of SATB2 and CDX2 expression is associated with DNA mismatch repair protein deficiency and BRAF mutation in colorectal cancer.
    Li J; Zeng Q; Lin J; Huang H; Chen L
    Med Mol Morphol; 2024 Mar; 57(1):1-10. PubMed ID: 37583001
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of DNA Mismatch Repair and Mutations in BRAF and KRAS With Survival After Recurrence in Stage III Colon Cancers : A Secondary Analysis of 2 Randomized Clinical Trials.
    Sinicrope FA; Shi Q; Allegra CJ; Smyrk TC; Thibodeau SN; Goldberg RM; Meyers JP; Pogue-Geile KL; Yothers G; Sargent DJ; Alberts SR
    JAMA Oncol; 2017 Apr; 3(4):472-480. PubMed ID: 28006055
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Deficient DNA mismatch repair is associated with favorable prognosis in Thai patients with sporadic colorectal cancer.
    Korphaisarn K; Pongpaibul A; Limwongse C; Roothumnong E; Klaisuban W; Nimmannit A; Jinawath A; Akewanlop C
    World J Gastroenterol; 2015 Jan; 21(3):926-34. PubMed ID: 25624727
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Concomitant expression patterns of CDX2 and SATB2 as prognostic factors in stage III colorectal cancers.
    Lee JA; Park HE; Jin HY; Jin L; Cho NY; Bae JM; Kim JH; Kang GH
    Ann Diagn Pathol; 2024 Aug; 71():152289. PubMed ID: 38555678
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mismatch repair phenotype determines the implications of tumor grade and CDX2 expression in stage II-III colon cancer.
    Hestetun KE; Aasebø K; Rosenlund NB; Müller Y; Dahl O; Myklebust MP
    Mod Pathol; 2021 Jan; 34(1):161-170. PubMed ID: 32737450
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinicopathologic and molecular features of sporadic early-onset colorectal adenocarcinoma: an adenocarcinoma with frequent signet ring cell differentiation, rectal and sigmoid involvement, and adverse morphologic features.
    Chang DT; Pai RK; Rybicki LA; Dimaio MA; Limaye M; Jayachandran P; Koong AC; Kunz PA; Fisher GA; Ford JM; Welton M; Shelton A; Ma L; Arber DA; Pai RK
    Mod Pathol; 2012 Aug; 25(8):1128-39. PubMed ID: 22481281
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Automated Quantitation of CD8-positive T Cells Predicts Prognosis in Colonic Adenocarcinoma With Mucinous, Signet Ring Cell, or Medullary Differentiation Independent of Mismatch Repair Protein Status.
    Hartman DJ; Frank M; Seigh L; Choudry H; Pingpank J; Holtzman M; Bartlett D; Bahary N; Pantanowitz L; Pai RK
    Am J Surg Pathol; 2020 Jul; 44(7):991-1001. PubMed ID: 32205483
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SATB2 Is Superior to CDX2 in Distinguishing Signet Ring Cell Carcinoma of the Upper Gastrointestinal Tract and Lower Gastrointestinal Tract.
    Ma C; Lowenthal BM; Pai RK
    Am J Surg Pathol; 2018 Dec; 42(12):1715-1722. PubMed ID: 30212392
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SATB2 Expression Distinguishes Ovarian Metastases of Colorectal and Appendiceal Origin From Primary Ovarian Tumors of Mucinous or Endometrioid Type.
    Moh M; Krings G; Ates D; Aysal A; Kim GE; Rabban JT
    Am J Surg Pathol; 2016 Mar; 40(3):419-32. PubMed ID: 26551622
    [TBL] [Abstract][Full Text] [Related]  

  • 14. KRAS and BRAF gene mutations and DNA mismatch repair status in Chinese colorectal carcinoma patients.
    Ye JX; Liu Y; Qin Y; Zhong HH; Yi WN; Shi XY
    World J Gastroenterol; 2015 Feb; 21(5):1595-605. PubMed ID: 25663779
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The prognostic impact of CDX2 correlates with the underlying mismatch repair status and BRAF mutational status but not with distant metastasis in colorectal cancer.
    Neumann J; Heinemann V; Engel J; Kirchner T; Stintzing S
    Virchows Arch; 2018 Aug; 473(2):199-207. PubMed ID: 29675807
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Possible role of Cdx2 in the serrated pathway of colorectal cancer characterized by BRAF mutation, high-level CpG Island methylator phenotype and mismatch repair-deficiency.
    Dawson H; Galván JA; Helbling M; Muller DE; Karamitopoulou E; Koelzer VH; Economou M; Hammer C; Lugli A; Zlobec I
    Int J Cancer; 2014 May; 134(10):2342-51. PubMed ID: 24166180
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential diagnostic and functional role of the multi-marker phenotype CDX2/CK20/CK7 in colorectal cancer stratified by mismatch repair status.
    Lugli A; Tzankov A; Zlobec I; Terracciano LM
    Mod Pathol; 2008 Nov; 21(11):1403-12. PubMed ID: 18587323
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diagnostic Utility of SATB2 in Metastatic Krukenberg Tumors of the Ovary: An Immunohistochemical Study of 70 Cases With Comparison to CDX2, CK7, CK20, Chromogranin, and Synaptophysin.
    Yang C; Sun L; Zhang L; Zhou L; Zhao M; Peng Y; Niu D; Li Z; Huang X; Kang Q; Jia L; Lai J; Cao D
    Am J Surg Pathol; 2018 Feb; 42(2):160-171. PubMed ID: 28914716
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of SATB2 and CDX2 Immunohistochemistry to Characterize and Diagnose Colorectal Cancer.
    Kato S; Koshino A; Lasota J; Komura M; Wang C; Ebi M; Ogasawara N; Kojima K; Tsuzuki T; Kasai K; Takahashi S; Miettinen M; Kasugai K; Inaguma S
    Appl Immunohistochem Mol Morphol; 2024 Sep; 32(8):362-370. PubMed ID: 39076030
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of SATB2 in distinguishing the site of origin in glandular lesions of the bladder/urinary tract.
    Giannico GA; Gown AM; Epstein JI; Revetta F; Bishop JA
    Hum Pathol; 2017 Sep; 67():152-159. PubMed ID: 28711650
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.